GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SIGA Technologies Inc (NAS:SIGA) » Definitions » Capex-to-Revenue

SIGA (SIGA Technologies) Capex-to-Revenue : 0.00 (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is SIGA Technologies Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

SIGA Technologies's Capital Expenditure for the three months ended in Sep. 2024 was $0.00 Mil. Its Revenue for the three months ended in Sep. 2024 was $10.01 Mil.

Hence, SIGA Technologies's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.00.


SIGA Technologies Capex-to-Revenue Historical Data

The historical data trend for SIGA Technologies's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SIGA Technologies Capex-to-Revenue Chart

SIGA Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SIGA Technologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SIGA Technologies's Capex-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, SIGA Technologies's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SIGA Technologies's Capex-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, SIGA Technologies's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where SIGA Technologies's Capex-to-Revenue falls into.



SIGA Technologies Capex-to-Revenue Calculation

SIGA Technologies's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.022) / 139.917
=0.00

SIGA Technologies's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 10.01
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SIGA Technologies  (NAS:SIGA) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


SIGA Technologies Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of SIGA Technologies's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SIGA Technologies Business Description

Traded in Other Exchanges
N/A
Address
31 East 62nd Street, New York, NY, USA, 10065
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Executives
Evan A. Knisely director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Jay Varma director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Ford Harold Eugene Jr. director 4921 WILLIAM ARNOLD ROAD, MEMPHIS TN 38117
James Antal director 30952 STEEPLECHASE DRIVE, SAN JUAN CAPISTRANO CA 92675
Holly L. Phillips director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Julian Nemirovsky director 35 EAST 62ND STREET, NEW YORK NY 10065
Edward P. Taibi director 35 EAST 62ND STREET, NEW YORK NY 10065
Jaymie A Durnan director C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK NY 10065
Gomez Phillip Louis Iii officer: Chief Executive Officer 7220 VAN NESS COURT, MCLEAN VA 22101
Daniel J Luckshire officer: Executive VP & CFO C/O SIGA TECHNOLOGIES, INC., 35 EAST 62ND STREET, NEW YORK NY 10065
Paul G Savas director 35 EAST 62ND STREET, NEW YORK NY 10021
Julie Kane director 77 BEALE ST, P.O. BOX 770000, SAN FRANCISCO CA 94177
Dennis E Hruby officer: Chief Scientific Officer SIGA TECHNOLOGIES, INC., 420 LEXINGTON AVENUE, SUITE 601, NEW YORK NY 10170
Michael J Bayer director 1100 N GLEBE ROAD, ARLINGTON VA 22201